Get the Stockscreener App
58.55
2.40%
-1.44
Belite Bio Inc Adr stock is traded at $58.55, with a volume of 19,927.
It is down -2.40% in the last 24 hours and down -9.08% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$59.99
Open:
$59.25
24h Volume:
19,927
Relative Volume:
0.61
Market Cap:
$1.99B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-49.86
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
-4.31%
1M Performance:
-9.08%
6M Performance:
-7.15%
1Y Performance:
+18.04%
1-Day Range:
$58.55
$60.35
1-Week Range:
$58.55
$62.48
52-Week Range:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
58.55 | 1.99B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat
Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria
Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks
Why Belite Bio’s Stock is Soaring High - TipRanks
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com
Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com
Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq
Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire
Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Morningstar
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia
Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks
Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks
Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria
Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com
Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat
Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Belite Bio reports Q1 EPS (45c), consensus (37c) - TipRanks
Belite Bio's Stargardt Disease Drug Passes Critical Phase 3 Trial Review, DSMB Suggests Regulatory Filing - Stock Titan
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.
Why Cigna Group Stock Dived Today - The Globe and Mail
Belite Bio, Inc to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference May 15th - GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences - Stock Titan
Belite Bio (BLTE) to Release Quarterly Earnings on Monday - Defense World
International companies to host live webcasts at Deutsche - GlobeNewswire
UPDATEInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results - Stock Titan
The 9 Best Stocks to Buy Now in May (2025)! - The Globe and Mail
Breakthrough: Belite Bio Presents Critical Data from Two Stargardt Disease Clinical Trials at ARVO 2025 - Stock Titan
Belite Bio, Inc (NASDAQ:BLTE) Shares Purchased by JPMorgan Chase & Co. - Defense World
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):